Abstract
Cardiovascular disease remains the leading cause of death worldwide. The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of blood pressure, through the actions of angiotensin (Ang) II. Excessive RAAS activity may lead to hypertension and associated target organ damage. Indeed, RAAS blockade with angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin receptor AT (1) blockers (ARBs) has proved to be successful treatment for arterial hypertension, heart failure and diabetes. Accumulating evidence suggests that arterial stiffness is an important and independent predictor of cardiovascular risk. More recently, a role for advanced glycation end-products (AGEs) in the development of arterial stiffening has been suggested. Advanced glycation end-products form by a nonenzymatic reaction between reducing sugars and biological proteins. Mechanisms underlying these alterations include AGE cross-linking of collagen and AGE interactions with circulating proteins and AGE receptors. New pharmacologic agents that prevent AGE formation, break cross-links, or block AGE receptors reduce vascular and myocardial stiffness, inhibit atherosclerotic plaque formation, and improve endothelial function. These agents promise to reduce the risk of isolated systolic hypertension, diastolic dysfunction, diabetes and thus, heart failure.
Keywords: Advanced glycation end products (AGEs), hypertension, diabetes, renin-angiotensin-aldosterone system (RAAS), arterial stiffness, AGE cross-link breakers, renin inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Volume: 5 Issue: 4
Author(s): A. Geronikaki, A. Gavalas, V. Dislian and G. Giannoglou
Affiliation:
Keywords: Advanced glycation end products (AGEs), hypertension, diabetes, renin-angiotensin-aldosterone system (RAAS), arterial stiffness, AGE cross-link breakers, renin inhibitors
Abstract: Cardiovascular disease remains the leading cause of death worldwide. The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of blood pressure, through the actions of angiotensin (Ang) II. Excessive RAAS activity may lead to hypertension and associated target organ damage. Indeed, RAAS blockade with angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin receptor AT (1) blockers (ARBs) has proved to be successful treatment for arterial hypertension, heart failure and diabetes. Accumulating evidence suggests that arterial stiffness is an important and independent predictor of cardiovascular risk. More recently, a role for advanced glycation end-products (AGEs) in the development of arterial stiffening has been suggested. Advanced glycation end-products form by a nonenzymatic reaction between reducing sugars and biological proteins. Mechanisms underlying these alterations include AGE cross-linking of collagen and AGE interactions with circulating proteins and AGE receptors. New pharmacologic agents that prevent AGE formation, break cross-links, or block AGE receptors reduce vascular and myocardial stiffness, inhibit atherosclerotic plaque formation, and improve endothelial function. These agents promise to reduce the risk of isolated systolic hypertension, diastolic dysfunction, diabetes and thus, heart failure.
Export Options
About this article
Cite this article as:
Geronikaki A., Gavalas A., Dislian V. and Giannoglou G., Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (4) . https://dx.doi.org/10.2174/187152507782109926
DOI https://dx.doi.org/10.2174/187152507782109926 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Class III Antiarrhythmics and Phenytoin: Teratogenicity Due to Embryonic Cardiac Dysrhythmia and Reoxygenation Damage
Current Pharmaceutical Design By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Antisense Antibiotics: A Brief Review of Novel Target Discovery and Delivery
Current Drug Discovery Technologies Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Current and Future Treatment Options in Idiopathic Pulmonary Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging Editorial (Hot Topic: No Reflow: What’s in a Name?)
Current Pharmaceutical Design Nutritional Supplements Modulating Metabolic Syndrome Risk Factors and the Prevention of Cardiovascular Disease
Current Nutrition & Food Science Mesenchymal Stem Cell-derived Exosomes Rescue Oxygen-Glucose Deprivation-induced Injury in Endothelial Cells
Current Neurovascular Research Humoral Immunity in Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine Cardiovascular Surveillance of Duchenne and Becker Muscular Dystrophy and Female Carriers
Current Pediatric Reviews Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms
Current Medicinal Chemistry Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry